Clinical trial
An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate an Pemetrexed Single Agent given as Neoadjuvant Treatment in Patients with Resectable Rectal Cancer
Evaluation of optimal dose of Methylenetetrahydrofolate (Modufolin) in combination with a fixed dose of Pemetrexed (Alimta) 500mg/m2 related to the safety margins as described.
| Category | Value |
|---|---|
| Study start date | 2010-01-13 |